Described is the development of a fluoroimmunoassay for theophylline using a fluorescein labelled derivative of theophylline as tracer and antibodies coupled to magnetisable solid-phase particles. Three approaches are described for the preparation of antibodies for theophylline, of which one produced highly specific, high titre antibodies. The fluoroimmunoassay using these antibodies required a 10 ul, sample, reached equilibrium within 5 min, and the results . correlated closely with those of an established enzymoimmunoassay method. Potentially interfering endogenous fluorophores from the serum sample were reliably removed at the separation step of the bound and free fractions. There was no significant cross-reactivity with all other structurally related compounds.
Theophylline (1,3-dimethylxanthine) is considered the drug of choice in the prevention and treatment of asthmatic symptoms in children and adults! and is also used for the treatment of apnea and bradycardia in infants.f It has a narrow therapeutic range and a wide variation in biological half-life, so the monitoring of serum theophylline levels is considered necessary for safe and effective use of the drug. 3--{j Various methods are available, as reviewed recently.P: 7 These include: spectrophotometry; gas chromatography; high pressure liquid chromatography; and radio and enzymoimmunoassay. The non-immunological methods all have disadvantages; they may require large sample volumes, and perhaps use technically complex and time consuming sample preparations. Immunoassays are simple, permit direct analysis with small sample volumes and allow large throughput. A theophylline immunoassay, however, requires highly-specific antibodies. This is due to the potential cross-reactivity of the major metabolites of the drug and the naturally occurring xanthines, caffeine (1,3,7-trimethylxanthine) and theobromine (3,7dimethylxanthine Several methods have been described for the production of anti-theophylline antibodies8--l0 and, due to the difficulty in raising highly specific antibodies, we followed three separate approaches. These were employed in the development of a fluoroimmunoassay for serum theophylline using a fluorescein labelled drug as tracer and antiserum covalently linked to magnetisable solid-phase particles. 11 
Materials and methods
Theophylline, bovine serum albumin (BSA) (type A4503), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), Nhydroxysuccinimide, fluorescein isothiocyanate isomer I (FITC), ethylenediamine dihydrochloride and most compounds for the crossreactivity studies were obtained from Sigma (Poole, Dorest, UK); 1-methylxanthine, 7-methylxanthine and 3-methyluric acid from Adams Chemical Co (Round Lake, Illinois, USA); Triton X-100 and all solvents (Analar grade) from BDH (Poole, Dorset, UK); keyhole limpet hemocyanin (KLH) from Calbiochem-Behring (Harwick, Cambridge, UK); Theophylline Enzyme Reagent B from an EMIT kit (Syva, Palo Alto, California, USA); normal human serum from ILS (London, UK); and silica gel thin layer chromatography sheets 5P (DC-Alufolien Kieselgel 60 F2S4 Art, 5554) from E Merck (Darmstadt, FRG).
SYNTHESIS OF THEOPHYLLINE
was condensed with glutaric anhydride as described by Cook et al.S
3-(4'-Carboxybutyl)-1-methylxanthine (theophylline-3-valeric acid)
I-Methyl-7-[(pivaloyloxy)methyl]xanthine was prepared from l-methylxanthine using chloromethylpivalate as described by Hu, Singh and Ullman.F The protected xanthine derivative (200 mg) was stirred in dimethylformamide (5 mL) with anhydrous sodium carbonate (151 mg) and methyl 5-bromovalerate (275 mg) under nitrogen at room temperature. After 12 h, water (10 mL) was added and the product extracted into chloroform (50 mL). The extract was washed with water (10 mL), dried with magnesium sulphate and evaporated to dryness to yield a yellow oil. Mass Spectrum analysis showed a molecular ion at 394 (ClsH24N406 requires 394).
The oily suspension in 2 M aqueous sodium hydroxide (20 mL) was refluxed under nitrogen for 2 h. The reaction mixture was cooled and acidified to pH 2-3 with 10% hydrochloric acid. The product, 3-(4' -carboxybutyl)-I-methylxanthine, separated as colourless needles which were filtered after cooling and washed with ice-cold water. The product (60 mg) had a molecular ion at 266 (CllH14N404 requires 266) and melting point of 205-206°C.
PREPARATION OF IMMUNOGENS AND

ANTI-THEOPHYLLINE SERA
Conjugation of theophylline-8-butyric acid to BSA 8-(3' -Carboxypropyl)-1 ,3-dimethylxanthine (40 mg) and EDC (40 mg) were reacted in 1 mL pyridine:water (1:1 by volume) and then added dropwise to a stirred solution of BSA (60 mg) in 2 mL of water. After 45 min the mixture was dialysed against 3 x 11 of distilled water over 3 days. The retentate was freeze-dried to yield 62 mg theophylline-8-butyric acid-BSA conjugate.
Immunisation
Three mature female Border-Leicester sheep were immunised following a previously described protocol. 13 Preparation of theophylline-3-butyric acid immunogen Enzyme reagent, prepared by conjugation of 3-(3' -carboxypropyl)-I-methylxanthine to glucose-6-phosphate dehydrogenase'" from an EMIT theophylline enzymoimmunoassay kit, was treated as described by Kamel ,'Landon and Smith. 15
Three female New Zealand white rabbits were immunised following a previously described protocol. IS
Conjugation of theophylline-3-valeric acid to KLH
3-(4' -Carboxybutyl)-I-methylxanthine (30 mg), N-hydroxysuccinimide (10 mg) and EDC (30 mg) were reacted in 1 ml pyridine: water (1:1 by volume) and then added dropwise to a stirred solution of KLH (70 mg) in 10 mL phosphate buffer (0,1 M, pH 7,0). After stirring for 24 h the mixture was dialysed against 3 x 11 of distilled water over 3 days. The retentate was freeze-dried to yield 60 mg theophylline-3valerie acid-KLH conjugate.
Immunisation
Three mature female Border-Leicester sheep were immunised following a previously described protocol. 13
ANTI-THEO P'HY LLIN E MAG N ETIS AB LE
SOLID-PHASE
Whole anti-theophylline sera were coupled to magnetisable cellulose following established procedures'!' 16 in the ratio of 2 mL sera per gram of solid-phase particles. The product was washed three times with assay diluent buffer, resuspended to 50 gIL and stored at 4°C.
PREPARATION OF
FLUORESCEIN-LABELLED THEOPHYLLINE
Preparation of fluoresceinthiocarbamyl ethylenediamine (FTC-ED)
FTC-ED was prepared from FITC and ethylenediamine dihydrochloride as described by Pourfarzaneh and his colleagues. IT
Conjugation of FTC-ED to theophylline-8-butyric acid
Theophylline-8-butyric acid (53 mg), EDC (40 mg) and FTC-ED (90 mg) were reacted for 2 h at room temperature in 5 mL of pyridine:water (4:1 by volume), then the solution was evaporated to dryness. The residue was redissolved in 500 IJ.L of methanol:ammonia (95:5 by volume), applied to silica gel sheets and developed with methanol:ammonia (95:5 by volume). The major band (R, 0·8) was scraped off and the product extracted into methanol and stored at -20 cC. The concentration was estimated spectrophotometrically.l"
Conjugation of FTC-ED to theophylline-S-valeric acid
Theophylline-3-valeric acid (4 mg) and EDC (8 mg) were reacted in 500 IJ.L pyridine:water (4:1 by volume) at room temperature for 15 min and then added dropwise to a stirred solution of FTC-ED (10 mg) in 500 IJ.L DMF:pyridine (1:1 by volume). After stirring for 2-3 h the reaction mixture was evaporated to dryness. The residue was redissolved in chloroform:methanol:ammonia (51:45:4 by volume), applied to silica gel sheets and developed with the same solvent mixture. The major band (R, 0·35) was scraped off and the product extracted into methanol and stored at -20 cC. The concentration was estimated spectrophotometrically.l" ASSAY STANDARDS A stock solution of 1 giL theophylline in water was diluted to 40, 20, 10, 5 and 2·5 mgIL in human serum. The standards were stored at 4 cC. Diluent buffer. For assay (A) and (B) use sodium borate (0,2 M, pH 9,5) containing Triton X-100 (1 mVL) and sodium azide (1 gIL); for assay (C) use TrisIHCl (0,2 M, pH 9,0) containing Triton X-100 (1 mVL) and sodium azide (1 giL).
PATIENT
Elution reagent. A mixture of methanol and sodium bicarbonate (0·05 M, pH 9,0) in the ratio of 70:30 by volume.
Fluoroimmunoassay for theophylline 521
Magnet rack. Immunostics FIA Multimagnetic Separator containing 60 polymer bonded rare earth (SmCOj ) permanent magnets (Seward Laboratory, Bedford, UK).
Fluorimeter. Fluorescence was measured directly in the disposable test tubes using a Model 1000 fluorimeter (Perkin-Elmer, Beaconsfield, Bucks, UK) as previously described by Nargessi and her colleagues. 18 Protocol. All assays were performed at room temperature in duplicate. To 10 or 100 IJ.L of standard or sample was added 100 IJ.L fluorescein-labelled theophylline, followed by 100 IJ.L anti-theophylline solid-phase. After incubation with constant shaking, 1 mL of diluent buffer was added, the solid-phase sedimented by replacing the rack in the Multimagnetic Separator and the supernates decanted to waste. Elution reagent (1·4 mL) was then added, the tubes vortexed and the solidphase again sedimented. Finally, the fluorescence of the supernates (containing the eluated bound fraction) was determined. A standard curve was constructed by plotting the percentage of total labelled theophylline fluorescence bound vs concentration of the standards.
Assay (A) was developed using: sheep antitheophylline-8-butyric acid solid-phase (25 gm/ L); FIC-ED labelled theophylline-8-butyric acid (600 nmol/L); 100 IJ.L standard or sample; 1 h incubation. Assay (B) was developed using: rabbit anti-theophylline-3-butyric acid solid-phase (30 giL); FIC-ED labelled theophylline-3valerie acid (525 nrnol/L) 100 IJ.L standard or sample; 1 h incubation. Assay (C) was developed using: sheep anti-theophylline-3-valeric acid solid-phase (12·5 giL); FIC-ED labelled theophylline-3valerie acid (225 nmol/L); 10 IJ.L standard or sample; 5 min incubation.
Results
ANTI-THEOPHYLLINE SERA
Sheep immunised with theophylline-8-butyric acid-BSA all responded with antibodies to theophylline. The cross-reactivity characteristics were similar, all showing marked crossreaction with both caffeine and theobromine. The third bleed from one animal was used for assay (A).
One rabbit immunised with theophylline-3butyric acid-enzyme conjugate did not respond. Two rabbits produced antibodies of low titre and with acceptable cross-reactivitycharacteris-tics. The third bleed from one of these was used for assay (B).
Sheep immunised with theophylline-3-valeric acid-KLH all responded with antibodies to theophylline, which exhibited low crossreactivity to caffeine and theobromine. The second bleed from one of these was used for assay (C).
ASSAY OPTIMISATION
The concentration of solid-phase which gave about 70% binding of the tracer in the absence of unlabelled drug was chosen from solid-phase antibody dilution curves performed using the assay protocol with doubling dilutions of solidphase in the absence of theophylline (zero concentration standard).
Incubation time was determined by studying the kinetics of theophylline binding to antitheophylline solid-phase. Incubation times of 5, 10, 20, 30, 60 and 120 min were tested. Time required to reach equilibrium was 60 min for assays (A) and (B) and 5 min for assay (C).
The standard curve covered the clinically important therapeutic and toxic concentration ranges for theophylline. A sample volume of 100 I-lL was necessary to achieve acceptable sensitivity in assays (A) and (B), while assay (C) needed only a 10 I-lL sample volume. Figure  1 shows a typical standard curve for assay (C).
Assay (A) validation
Specificity. The cross-reactivities of caffeine and theobromine were calculated as described by Abraham'? and were 120% and 40% respectively. 3-Methylxanthine showed undetectable cross-reaction at 1 giL.
Due to the non-specific nature of the antisera no further validation was undertaken.
Assay (B) validation
Specificity. The cross-reactivities of caffeine and theobromine were calculated as above and were 10% and 5% respectively. 3-Methylxanthine cross-reacted less than 1% at 1 gIL.
Precision. Three pools of selected patients' sera were each assayed 10 times in duplicate in one assay and on 10 different days. Withinassay coefficients of variation (CYs) were 6·0, 5·2 and 2·8% at mean theophylline levels of 5,6,16·0 and 31·6 mg/L respectively. Betweenassay CYs were 8,0, 6·4 and 5·0% at these levels.
Accuracy. Theophylline was added to normal human serum at levels of 5·0, 15·0 and 30·0 mg/L, Analytical recovery was 112,0, 106·0 and 105·0% respectively.
Correlation. Results of the assay of 32 patients' serum specimens by fluoroimmunoassay (y) and by enzymoimmunoassay (x) were related by the regression line y = 0·98x + 0·2, with a correlation coefficient (r) of 0·98.
Assay (C) validation
Specificity. The cross-reactivities of various closely related compounds in the assay are summarised in Table 1 . For l-methylxanthine '" E
STABILITY OF REAGENTS
There was no change in the properties of the fluorescein labelled theophylline stored in methanol at -20°C over a I-year period or of the anti-theophylline solid-phase stored at 4°C for a similar period. and 8-chlorotheophylline the cross-reactivity was calculated according to Abraham.l" The cross-reactivity of the other compounds is at a concentration of 1 giL. Precision. Three pools of selected patients' sera were each assayed 10 times in duplicate in one assay and on 10 different days. Withinassay CVs were 5·9, 5·0 and 4·3% at mean theophylline levels of 3·6, 14·0 and 28·0 mgIL respectively. Between assay CVs were 7,1, 5·6 and 5·6% at these levels.
Accuracy. Theophylline was added at known concentrations to patients' serum samples with initial drug levels of 0,0, 6,0, 7·0, 11·0 and 13·5 mgIL. Analytical recovery of 5·0, 10·0 and 20·0 mgIL added theophylline averaged 101·2%, 104·3% and 103·7% respectively.
Correlation. Results of the assay of 65 patients' serum samples by fluoroimmunoassay (y) and by enzymoimmunoassay (x) were related by the regression line y = 0·996x -0·44, with a correlation coefficient (r) of 0·97 (Fig.  2) . 
Discussion
The specificity of the antibody is of major importance when developing an immunoassay for theophylline. The similarily structured caffeine and theobromine are widely consumed in the form of tea, coffee, cocoa and soft drinks. Other potential crossreactants are the metabolites of theophylline and naturally occurring xanthines. Therefore the theophylline immunogen needs to be carefully designed to minimise these possible interferences. The first immunogen used was a theophylline derivative with a protein carrier linked via the 8-positfon 8 (theophylline-Ssbutyric acid.-BSA conjugate). This should leave the 1, 3, 7 and 9 positions free for antibody selectivity. But antibodies raised to this preparation all exhibited marked crossreactivity with the 7substituted xanthines. This suggests that acylation of the N-7 (and/or N-9) position occurred during the carbodiimide reaction. The immunogen would then be a mixture, with BSA linked via the 7, 8 and 9 positions, and consequently the antibodies produced would be non-specific, as observed (Fig. 3) .
The next approach was to raise antibodies using a readily available theophylline-enzyme conjugate (theophylline-3-butyric acid-glucose-6-phosphate dehydrogenase conjugate). This provided a quick, simple immunogen with the enzyme linked via the 3-position. The coupling of a carrier protein in this position has been shown by Singh et al. 9 to produce specific antibodies for theophylline. They hypothesised that the methyl group at the 3-position was of limited importance to precise molecular differentiation between the possible cross-reacting compounds and theophylline, and that by using a 3-carboxyalkyl linkage the electronic and steric characteristics at this site would be retained. The antibodies were raised in rabbits due to the small quantity of immunogen (ug amounts) available. Though the crossreactivities with caffeine and theobromine were acceptable, the antibody titres were low.
We finally immunised sheep with theophylline-3-valeric acid conjugated to KLH, a large antigenic molecule, repeating the linkage via the 3-position. All three sheep responded with highly specific, high titre antibodies. The theophylline fluoroimmunoassay developed using antiserum from one of these sheep gave no significant cross-reactivity with all other structurally related compounds tested. It required a small sample volume (10 ul.), no sample pretreatment and a short incubation time (5 min). These are important considerations when measuring samples from infants or children and in emergency situations. The assay used non-radioactive, stable reagents and a simple filter fluorimeter for quick, precise end-point detection. The separation step facilitated by magnetic sedimentation enabled the quick and reliable removal of serum fluorophores and other potentially interfering compounds. 20 
